Chesapeake Urology Associates Presents Significant Financial Gift To Urology Care Foundation In Support Of Critical Prostate Cancer Research - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Chesapeake Urology Associates Presents Significant Financial Gift To Urology Care Foundation In Support Of Critical Prostate Cancer Research


Chesapeake Urology Associates Presents Significant Financial Gift To Urology Care Foundation In Support Of Critical Prostate Cancer Research

PR Newswire

OWINGS MILLS, Md., June 27, 2014 /PRNewswire-USNewswire/ -- In ongoing support of prostate cancer research, Sanford Siegel, M.D., President and CEO of Chesapeake Urology Associates, presented the Urology Care Foundation with a check for $114,248 in support of its prostate cancer research efforts. The funds, which were raised through the Zero Prostate Cancer Challenge (ZPCC) 10K/5K run in September 2013, were presented at the AUA Annual Meeting in Orlando, Florida on May 16, 2014.  The Urology Care Foundation is the official foundation of the American Urological Association (AUA)—an organization of roughly 20,000 urologists.

Dr. Richard Memo, Chair of Urology Care Foundation Board of Directors (left), Dr. Sanford Siegel, President and CEO,
               Chesapeake Urology Associates (center), and Dr. Johannes Vieweg, AUA Research Council Chair (right).

Chesapeake Urology Associates, a leading proponent for the advancement of critical prostate cancer research, is proud to sponsor the Chesapeake Urology Prostate Fund at the Urology Care Foundation and, to date, has raised nearly $900,000 through its fundraising efforts to benefit prostate cancer research, education, as well as free screenings for men throughout the Greater Baltimore region. Chesapeake Urology anticipates reaching its goal of $1 million endowment for the prostate fund in 2015.

"Prostate cancer takes the lives of more than 30,000 men every year," says Dr. Siegel. "Because of this staggering statistic, Chesapeake Urology remains committed to ending prostate cancer by helping to find a cure through the support of groundbreaking research and free screening programs."

In support of this commitment, Chesapeake Urology created The Great Prostate Cancer Challenge® (GPCC) in 2007,  a fundraising initiative solely focused on prostate cancer research, awareness, and free screenings for men in need. It is the only physician-based awareness and fundraising program in the country and has been adopted by 40 urology practices in 36 cities nationwide since its inception. In 2013, the Great Prostate Cancer Challenge became the ZERO Prostate Cancer Challenge to raise greater awareness of prostate cancer and the nonprofit, ZERO-The End of Prostate Cancer.

ZERO Prostate Cancer Challenge Annual 5K run / 1 Mile Fun Walk

The ZERO Prostate Cancer Challenge fundraising efforts are focused around an annual 5K/1 Mile Fun Walk each September during National Prostate Cancer Awareness Month. This event, along with other events throughout the year including the Great Prostate Cancer Challenge Baltimore Golf Classic, which teams up with LPGA tour players to help in the fight against prostate cancer, generates financial support to help end prostate cancer through research. Since its inception, Chesapeake Urology physicians and staff, patients and families, and friends of the ZPCC have helped raise more than $2 million in Baltimore to assist in finding a cure and spreading awareness of prostate cancer. Funds from The ZERO Prostate Cancer Challenge are donated to the nonprofits, ZERO-The Project to End Prostate Cancer and the Urology Care Foundation in an effort to advance prostate cancer research with the hope of one day finding a cure for the devastating disease.  

Free Prostate Cancer Testing for Men in Need

A portion of the money raised from the ZPCC also remains local, funding a number of free prostate cancer screenings each year throughout the Baltimore Metro area. The locations of the screening events are carefully chosen and are held in areas with an underserved population. Since African- American men are at a 60 percent greater risk of this disease, Chesapeake Urology partners with many African American churches in the Baltimore area and Chesapeake Urology doctors and staff volunteer their time and expertise at these health events. To date, Chesapeake Urology has screened more than 4,000 men through this program.

Chesapeake Urology Research Associates

Chesapeake Urology Research Associates (CURA)  is the research component of Chesapeake Urology, dedicated to research and clinical trials for a variety of urologic conditions, including prostate cancer.  Staffed by an experienced team of physicians and certified research coordinators, patients have access to advanced therapies and technology through clinical trials even before they are available to the general public.  There are currently several clinical research trials available to prostate cancer patients through Chesapeake Urology Research Associates. More information on these trials can be found here.

About Chesapeake Urology

Chesapeake Urolog y is a fully-integrated urology practice providing a comprehensive array of urologic services to its patients. The Company operates 21 medical offices and 16 AAAHC-certified ambulatory surgery centers in Baltimore, Harford, Howard, Carroll, Montgomery , Prince George's, Charles and Anne Arundel counties and in Baltimore City , and has a staff of 475 including 59 physicians. Chesapeake was recently named one of the top 100 places to work in healthcare nationally by Modern Healthcare magazine.   For information about Chesapeake Urology, please visit ChesapeakeUrology.com.

CONTACT:
Patricia Schnably, Chesapeake Urology Associates
443-738-8107; pschnably@cua.md; ChesapeakeUrology.com

Chesapeake Urology Associates logo.

Photo - http://photos.prnewswire.com/prnh/20140627/122624
Logo - http://photos.prnewswire.com/prnh/20131205/MM28584LOGO

SOURCE Chesapeake Urology Associates

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
7%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here